Literature DB >> 12933820

Brief bone morphogenetic protein 2 treatment of glucocorticoid-inhibited MC3T3-E1 osteoblasts rescues commitment-associated cell cycle and mineralization without alteration of Runx2.

Cynthia A Luppen1, Nathalie Leclerc, Tommy Noh, Artem Barski, Arvinder Khokhar, Adele L Boskey, Elisheva Smith, Baruch Frenkel.   

Abstract

Glucocorticoids (GCs) inhibit bone formation in vivo. In MC3T3-E1 osteoblasts, chronic administration of 1 microm dexamethasone (DEX) starting at confluency results in >98% inhibition of bone morphogenetic protein 2 (BMP-2) expression and apatite mineral deposition. Here, it is shown that brief exposure to recombinant human BMP-2 (rhBMP-2), as short as 6 h, is sufficient to induce irreversible commitment to mineralization in DEX-treated cultures. RhBMP-2 dose dependently rescued mineralization but not collagen accumulation in DEX-inhibited cultures. The selective restoration of mineralization was evident in the higher mineral to matrix ratios of DEX/rhBMP-2 co-treated cultures compared with control. We tested the involvement of the runt-related transcription factor 2 (Runx2) in the DEX inhibition and rhBMP-2 rescue of mineralization. Surprisingly, DEX did not decrease Runx2 DNA binding activity, transactivation, or association with the endogenous osteocalcin gene promoter. Furthermore, the rhBMP-2 rescue did not involve Runx2 stimulation, suggesting an important role for factors other than Runx2 in BMP-2 action. Finally, we studied the differentiation-related cell cycle, which persists during commitment to mineralization in untreated cultures, but is inhibited along with mineralization in DEX-treated cultures. Although both rhBMP-2 alone and DEX alone were antimitogenic, rhBMP-2 stimulated this cell cycle in DEX-inhibited cultures. In conclusion, brief rhBMP-2 treatment restores mineralization in DEX-inhibited MC3T3-E1 osteoblasts via a mechanism different from Runx2 stimulation. This restoration may be functionally related to the accompanying rescue of the differentiation-related cell cycle. The efficacy of short term BMP-2 treatment supports the potential of short-lived BMP vectors for skeletal therapy in both traditional and gene therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12933820     DOI: 10.1074/jbc.M306730200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  ChIP Display: novel method for identification of genomic targets of transcription factors.

Authors:  Artem Barski; Baruch Frenkel
Journal:  Nucleic Acids Res       Date:  2004-07-13       Impact factor: 16.971

Review 2.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.

Authors:  Yu Shao; Emily Wichern; Paul J Childress; Michele Adaway; Jagannath Misra; Angela Klunk; David B Burr; Ronald C Wek; Amber L Mosley; Yunlong Liu; Alexander G Robling; Nickolay Brustovetsky; James Hamilton; Kylie Jacobs; Deepak Vashishth; Keith R Stayrook; Matthew R Allen; Joseph M Wallace; Joseph P Bidwell
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-01-15       Impact factor: 4.310

4.  Progressive recruitment of Runx2 to genomic targets despite decreasing expression during osteoblast differentiation.

Authors:  Steven Pregizer; Sanjeev K Baniwal; Xiting Yan; Zea Borok; Baruch Frenkel
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

5.  Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.

Authors:  Unnati Jariwala; Jon P Cogan; Li Jia; Baruch Frenkel; Gerhard A Coetzee
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

6.  Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity.

Authors:  Jen-Chywan Wang; Nilesh Shah; Carlos Pantoja; Sebastiaan H Meijsing; Joseph D Ho; Thomas S Scanlan; Keith R Yamamoto
Journal:  Genes Dev       Date:  2006-03-15       Impact factor: 11.361

7.  Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation.

Authors:  Karl Wu; Tzu-Hung Lin; Houng-Chi Liou; Dai-Hua Lu; Yi-Ru Chen; Wen-Mei Fu; Rong-Sen Yang
Journal:  Osteoporos Int       Date:  2013-02-12       Impact factor: 4.507

8.  Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity.

Authors:  Phimon Atsawasuwan; Yoshiyuki Mochida; Michitsuna Katafuchi; Masaru Kaku; Keith S K Fong; Katalin Csiszar; Mitsuo Yamauchi
Journal:  J Biol Chem       Date:  2008-10-02       Impact factor: 5.157

9.  BMP-2 vs. BMP-4 expression and activity in glucocorticoid-arrested MC3T3-E1 osteoblasts: Smad signaling, not alkaline phosphatase activity, predicts rescue of mineralization.

Authors:  Cynthia A Luppen; Ronald L Chandler; Tommy Noh; Douglas P Mortlock; Baruch Frenkel
Journal:  Growth Factors       Date:  2008-08       Impact factor: 2.511

10.  Functional enhancers at the gene-poor 8q24 cancer-linked locus.

Authors:  Li Jia; Gilad Landan; Mark Pomerantz; Rami Jaschek; Paula Herman; David Reich; Chunli Yan; Omar Khalid; Phil Kantoff; William Oh; J Robert Manak; Benjamin P Berman; Brian E Henderson; Baruch Frenkel; Christopher A Haiman; Matthew Freedman; Amos Tanay; Gerhard A Coetzee
Journal:  PLoS Genet       Date:  2009-08-14       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.